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Lentiviruses exist in vivo as a population of related, nonidentical genotypes, commonly referred to as
quasispecies. The quasispecies structure is characteristic of complex adaptive systems and contributes to the
high rate of evolution in lentiviruses that confounds efforts to develop effective vaccines and antiviral therapies.
Here, we describe analyses of genetic data from longitudinal studies of genetic variation in a lentivirus
regulatory protein, Rev, over the course of disease in ponies experimentally infected with equine infectious
anemia virus. As observed with other lentivirus data, the Rev variants exhibited a quasispecies character.
Phylogenetic and partition analyses suggested that the Rev quasispecies comprised two distinct subpopulations
that coexisted during infection. One subpopulation appeared to accumulate changes in a linear, time-depen-
dent manner, while the other evolved radially from a common variant. Over time, the two subpopulations
cycled in predominance coincident with changes in the disease state, suggesting that the two groups differed in
selective advantage. Transient expression assays indicated the two populations differed significantly in Rev
nuclear export activity. Chimeric proviral clones containing Rev genotypes representative of each population
differed in rate and overall level of virus replication in vitro. The coexistence of genetically distinct viral
subpopulations that differ in phenotype provides great adaptability to environmental changes within the
infected host. A quasispecies model with multiple subpopulations may provide additional insight into the
nature of lentivirus reservoirs and the evolution of antigenic and drug-resistant variants.
Lentiviruses exhibit high mutation rates and exist in vivo as
a population of closely related viral genotypes that are com-
monly referred to as a quasispecies (11, 13, 19). The popula-
tion structure of a quasispecies consists of a master sequence,
which is the dominant genotype, and the mutant spectrum,
which includes reservoirs of genotypic and phenotypic variants
with the potential to become dominant in the face of environ-
mental change. Studies have demonstrated that the evolution
of viral quasispecies adheres to basic principles of population
genetics; however, quasispecies theory diverges from popula-
tion genetics in that the entire deme of related sequences,
rather than the individual replicon, is the main target of selec-
tion (14). The quasispecies occupies a region on a fitness land-
scape where adaptive mutations move the quasispecies toward
a fitness peak, thereby increasing the mean fitness of the qua-
sispecies. Understanding the principles that shape the evolu-
tion of viral quasispecies is becoming increasingly important as
molecular information is used to model disease progression
and to predict the emergence of antigenic and drug-resistant
variants.
Experimental infection of ponies with equine infectious ane-
mia virus (EIAV) provides an excellent system for longitudinal
studies of lentivirus evolution during disease progression.
EIAV is a lentivirus that is genetically (21), antigenically (31),
and morphologically (15) related to human immunodeficiency
virus type 1 (HIV-1). In ponies, EIAV induces a reproducible
clinical disease course with progression of clearly demarcated
stages of disease (17, 20, 22, 29). Upon infection, animals may
suffer an early episode of acute illness, including fever and
thrombocytopenia associated with high levels of virus replica-
tion. Resolution of acute illness occurs concurrently with the
appearance of a virus-specific cytotoxic T-lymphocyte (CTL)
response and a decrease in the level of plasma viremia (16, 30).
In the chronic stage, recurrent episodes of high-titer viremia
and associated disease often occur within the first year after
initial infection but generally abate in frequency and severity
with time. Thereafter, most horses enter an inapparent carrier
state with no apparent compromises in their long-term health
and activity. Nonetheless, these individuals do not clear the
virus and remain persistently infected throughout their life (18,
23, 26, 32, 38).
We and others have observed genetic variation in the region
of the EIAV genome where the second exon of Rev overlaps
the cytoplasmic portion of the transmembrane protein (2, 5,
27). Rev is a regulatory protein that controls nuclear export of
unspliced and singly spliced viral mRNAs, which are essential
for virus replication. Therefore, factors that modulate Rev
activity and, consequently, alter levels of viral gene expression
may be important in regulating virus replication in vivo. To
examine this possibility, we recently undertook a comprehen-
sive longitudinal analysis of genetic and biological variation in
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Rev throughout a clinically dynamic disease course in one pony
experimentally infected with the virulent EIAVWyo2078 (4).
The pony experienced multiple febrile cycles during the first 4
months of infection. The onset of the inapparent period coin-
cided with the appearance of detectable neutralizing antibody,
consistent with previous evidence that clinical quiescence is
associated with the development of broadly reacting virus neu-
tralizing antibody and maturation of the immune response
(16). Changes in the genotype and phenotype of Rev quasi-
species correlated with changes in clinical stages of EIAV
infection: Rev variants predominant during chronic febrile pe-
riods had significantly higher Rev-mediated nuclear export ac-
tivity than the variants predominant during the inapparent
stage of disease. Therefore, the onset of clinical latency was
associated with the maturation of the host immune response
and a significant decrease in Rev activity.
In the present study, we used phylogenetic and biological
analyses to characterize the evolution of EIAV Rev variants in
vivo. Results identified two distinct subpopulations of rev that
evolved in different patterns, coexisted during disease, and
differed in phenotype. A quasispecies comprised of multiple
subpopulations that occupy different regions on a fitness land-
scape could allow a virus to adapt rapidly to changes in the host
environment by expanding minor, less fit populations that may
be near the new fitness peaks. Such a model may provide new
insight into the factors that shape the evolution of viral quasi-
species during progression of disease.
MATERIALS AND METHODS
Experimental infections and identification of Rev variants. The virulent Wy-
oming strain of EIAV was used to infect pony 524, and sequential serum samples
were collected from different stages of clinical disease, as previously described
(4). Pony 625 was inoculated intravenously with 2 ml of heparinized plasma
collected from pony 524 at 878 days postinfection. These inocula are heteroge-
neous populations of virus, similar to a natural infection.
Viral RNA isolated from the inoculum and from sera collected during variable
stages of disease was reverse transcribed and amplified with primers to conserved
regions of EIAV (Fig. 1). PCR amplification conditions consisted of 37 cycles of
denaturation at 94°C for 2 min, annealing at 50°C for 1 min, and extension at
72°C for 1 min. The initial and final cycles contained a prolonged extension at
72°C for 5 min. Then 2 l of PCR product was cloned into pGEM-T vectors as
recommended by the manufacturer (Promega, Madison, Wis.) and transformed
into Escherichia coli DH5. Clones were sequenced bidirectionally with primers
to vector sequences flanking the insert. Sequencing was performed by the Iowa
State University DNA Synthesis and Sequencing Facility with an automated
DNA sequencer. Sequences were aligned by MacVector and AssemblyLIGN
software (Oxford Molecular, Beaverton, Oreg.).
For pony 524, we analyzed 61 rev clones from the inoculum and 23 to 25 clones
from each of 11 sequential serum samples taken at 12, 35, 67, 89, 118, 201, 289,
385, 437, 754, and 800 days postinfection. In addition, 20 clones spanning the
EIAV Rev-responsive element (RRE) were analyzed from the inoculum and
serum samples collected at 12, 118, 385, and 800 days postinfection. Sixteen
clones were analyzed from the pony 625 inoculum and 13 to 21 clones from each
of five sequential serum samples collected at 14, 25, 46, 67, and 77 days postin-
fection. Rev amino acid variants were named in the order they were identified,
with identical variants given the same name. The names for pony 625 Rev
variants were continued from the numbering of pony 524 variants.
Analysis of viral quasispecies. Phylogenetic analyses were used to characterize
the genetic relationship among Rev amino acid variants in each horse. The
neighbor-joining distance method based on p-distance was used to construct
unrooted phylogenetic trees from the Rev amino acid sequences with Mega
versions 1.01 and 2.1 (24, 25). Other methods for estimating amino acid substi-
tutions between clones, i.e., number of amino acid differences, Poisson-corrected
distance, and gamma distance, were also used and resulted in trees nearly
identical to those presented in this paper. Tree-Puzzle (36) was used to assess the
support for particular clades in the phylogenetic tree with likelihood mapping
(37). Briefly, the relative support, based on a maximum-likelihood analysis, is
inferred for each of the three possible tree topologies for random quartets of
sequences. The data are reported as the percentage of random quartets support-
ing the hypothesized clades; ambiguous results were not counted as supportive of
any clade (37). Tree-Puzzle can use any of the standard maximum-likelihood
models of protein evolution. We used the JTT model with empirical amino acid
frequencies estimated from the data and no rate variation among sites.
The program PAQ, for partition analysis of quasispecies (3), was used to group
the rev genotypes that were most similar at each time point. The program uses
the Hamming distance as a measure of distance between rev variants and a
nonhierarchical clustering method to identify discrete and cohesive partitions of
closely related sequences, similar to other clustering algorithms (28). However,
PAQ does not select a predetermined number of partitions, and overlap between
partitions is allowed. The optimal output maximizes the number of variants
contained within the partition while minimizing the partition radius and any
overlap between partitions. The central genotype of each group is the sequence
most representative of all variants within the group. A standard comparison of
two population means was used to determine whether distances within each
group were statistically different from distances between two groups. A z-statistic,
assuming a normal distribution, was calculated with the mean and variance of the
two populations and tested under the criterion of P  0.01.
Construction of Rev expression plasmids and CAT assays. Selected Rev vari-
ants were subcloned into a Rev expression vector and assayed for nuclear export
activity as previously described (5). pERevWT, which was previously described as
pcH21 (4), contains Rev cDNA in the pCR3 background (Invitrogen, Carlsbad,
Calif.). The rev exon 2 was removed by digestion with the restriction endonucle-
ase ApaI. The digested plasmid was gel purified, dephosphorylated, and ligated
with the exon 2 sequence of rev variants as described (4, 5). All clones were
confirmed by sequencing.
Rev-dependent nuclear export activity was determined in transient transfec-
FIG. 1. (A) Organization of EIAV open reading frames, with solid black lines indicating regions amplified, cloned, and sequenced. The minimal
EIAV Rev-responsive element (RRE; see below) is contained within the S2/gp90 amplified region, which spans nucleotides 5233 to 5589. The
rev/gp45 amplified region spans nucleotides 7066 to 7680. (B) The EIAV Rev reporter plasmid pERRE-All contains nucleotides 5280 to 7534. The
small shaded area indicates the 57-nucleotide region (nucleotides 5485 to 5540) within ERRE-All that was found to comprise a minimal RRE (6).
(C) Representation of the Rev chimeric proviral clones. The shaded area in the overlapping rev/tm region indicates the portion containing Rev
variant sequences. Numbering is based on that of Kawakami et al. (21).
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tion assays with the pERRE-All reporter plasmid (5), a derivative of pDM138
with an intron containing the chloramphenicol acetyltransferase (CAT) gene and
EIAV nucleotides 5280 to 7534 (Fig. 1b). 293T cells were transfected with 1 g
of either pcDNA3 or Rev variant plasmid, 0.2 g of pERRE-All reporter plas-
mid, 0.2 g of pCH110 (Amersham Pharmacia Biotech, Piscataway, N.J.), and
0.6 g of pUC19 by calcium phosphate coprecipitation. Each experiment also
included a sham group that contained no reporter plasmid but an additional 0.2
g of pUC19. Two days posttransfection, cells were harvested, resuspended in
0.3 ml of 0.25 M Tris (pH 7.5), lysed by freeze/thawing, and assayed for -ga-
lactosidase activity to normalize CAT assays for transfection efficiency. Normal-
ized lysates were assayed for CAT activity in a 0.1-ml volume with 3 l of
[14C]chloramphenicol and 1 mM acetyl-coenzyme A. Acetylated products were
separated by thin-layer chromatography, and the percentage of acetylation was
quantified by phosphorimager. In some experiments, the amount of CAT enzyme
was quantified with a commercial enzyme-linked immunosorbent assay (ELISA)
kit (Roche, Indianapolis, Ind.). Experiments were performed in triplicate, and
results summarize a minimum of nine transfections. Statistical significance was
determined by analysis of variance.
Construction and analysis of chimeric virus. Chimeric proviruses were con-
structed in the backbone of pSPEIAV19, an infectious molecular clone of EIAV
(34). To facilitate cloning, pSPEIAV19 was digested with SphI and EcoRI and
the 3 half of the EIAV provirus was subcloned into pLG338/30 (34), generating
a shuttle plasmid that included the rev/tm overlapping region. The shuttle plas-
mid was digested with ApaI and BstBI to remove the rev/tm region. This region
was replaced with the similar 403-bp insert isolated from Rev variant cDNAs by
ApaI and BstBI digestion and gel purification. The SphI-EcoRI fragment con-
taining rev/tm variants was excised from the shuttle plasmid, isolated, and rein-
serted into the pSPEIAV19 backbone, generating full-length proviral clones that
differed only in the rev/tm overlapping region (Fig. 1c). Chimeric proviral plasmid
DNAs were purified and confirmed by sequence analysis.
To generate chimeric virus stocks, 1.9 g of proviral DNA and 0.1 g of
pSV5neo were cotransfected into canine fetal thymus cells (Cf2th; ATCC CRL-
1430) with TransIT-LT1 (Mirus Corporation, Madison, Wis.). At 2 days post-
transfection, cells were passed into 100-mm tissue culture dishes and grown in
Dulbecco’s modified Eagle’s medium supplemented with 2-mg/ml G418. Surviv-
ing cell colonies were tested for supernatant reverse transcriptase (RT) activity
(8), and RT-positive clones were used for production of chimeric virus stocks.
The identity of the rev/tm insert in the virus stock was confirmed by sequence
analysis. To assess the effect of variation on virus replication, chimeric virus
stocks were normalized by RT activity and 104 cpm was inoculated onto equine
dermal cells (ED; ATCC CCL57) seeded the previous day at 105 cells/well in
24-well tissue culture plates in Dulbecco’s modified Eagle’s medium supple-
mented with 20% fetal bovine serum and penicillin/streptomycin. Supernatant
was collected every 2 days, and virus replication was quantified by supernatant
RT activity (8).
Nucleotide sequence accession numbers. GenBank accession numbers are
AF314257 to AF314404 and AF512608 to AF512669.
RESULTS
Subpopulations identified in Rev quasispecies of EIAV-in-
fected horses. Following experimental infection, pony 524 ex-
perienced a variable clinical disease course characterized by
recurring fever cycles interspersed with afebrile periods rang-
ing from days to months (Fig. 2). The onset of the inapparent
stage was associated with the maturation of the host immune
response and a significant decrease in Rev activity (4). Here,
we examined the evolution of EIAV Rev quasispecies during
infection of pony 524. A neighbor-joining tree was constructed
to elucidate the genetic relatedness of the entire data set of
pony 524 Rev amino acid variants. The phylogenetic tree dis-
played a distinct branching pattern of Rev variants into two
major clades, designated clade A and clade B, and a minor
clade, designated clade C (Fig. 3). However, the combination
of low genetic diversity and short but numerous sequences
resulted in low bootstrap support for the branch point sepa-
rating clades A and B (10%).
To test whether clade A and clade B were indeed monophy-
letic, likelihood mapping (37) with Tree Puzzle (36) was em-
ployed. Of the 1,000 random quartets sampled, 89.3% sup-
ported the distinct clades A and B. In addition, when separate
phylogenetic trees were inferred with neighbor-joining for each
time point sampled, the bootstrap support for clades A and B
steadily increased from 50% at early time points to 99% and
100% for the last two time points, respectively (data not
shown). Therefore, despite the low bootstrap support, the phy-
logenetic tree (Fig. 3) captures the basic evolutionary patterns
of the Rev variants isolated from pony 524.
Both clade A and clade B contained variants from the inoc-
ulum and from each stage of disease; however, there were
marked differences in topology between the clades that sug-
gested they had evolved under different selective mechanisms.
Clade A was characterized by transience and divergence of
Rev variants over the course of infection such that late time
points appear to nest as monophyletic groups within earlier
time points. Genetic variation within this clade was relatively
large, with 8 amino acid differences between R3 and R94. In
contrast, all of the sequences in clade B were genetically very
similar, with a maximum of three amino acid differences be-
tween any two variants. Clade B variants came from all stages
of disease and appeared to evolve radially away from R1, the
major founder variant in the inoculum (4).
To confirm this, we again applied likelihood mapping, this
time independently within clade A and clade B. The results
supported increased diversity and linear evolution in clade A,
contrasting with low diversity and radial evolution in clade B
(not shown). The minor clade, clade C, contained only seven
variants. The genetic variation within clade C was the same as
clade A (eight amino acid differences), but unlike clade A,
FIG. 2. Febrile response of ponies 524 and 625 following experimental infection. The temperature of the ponies was measured daily during
clinical episodes and intermittently during chronic clinical disease. Febrile episodes (defined as 100°F or higher) are shown for each pony.
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there was no incremental progression of variation. It is possible
that additional clade C variants were present throughout all
stages of infection, but existed at levels too low to be detected
by our sampling procedures. Therefore, the origin and biolog-
ical significance of this minor clade are uncertain at this time.
The population structure of rev quasispecies was examined
in a second horse, pony 625, which was inoculated with serum
from pony 524 collected at 878 days postinfection. Pony 625
underwent several febrile cycles over the acute and chronic
stages of disease, became moribund, and was euthanized at 89
days postinfection (Fig. 2). Viral RNA was isolated from the
inoculum and from serum samples collected at sequential
FIG. 3. Neighbor-joining tree of the pony 524 Rev amino acid variants based on p distance. The tree is divided into three clades, designated
clades A, B, and C. The stage of disease from which the Rev variants were isolated is indicated by the color of its branch. Multicolored branches
indicate variants isolated at multiple stages of disease. Highlighted variants were assayed for Rev activity.
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times postinfection. Sequence analysis identified a heteroge-
neous population of Rev variants in the inoculum and through-
out infection (Fig. 4). The predominant sequence at every time
point examined was R93, a variant that was predominant in
pony 524 late in infection (4). A minor group of related se-
quences, represented by R103, was also present in the inocu-
lum and most time points examined (except 14 days postinfec-
tion). R103 differed from R93 at eight amino acid positions,
but only differed by two amino acids from R1 (which was not
observed in pony 625).
Phylogenetic analysis of pony 625 variants identified two
clades, designated clade A and clade B (Fig. 5a); clade A
included R93 and related variants, and clade B included R103
and related variants. The variation between these two clades
was more distinct and was supported by higher bootstrap val-
ues (82%). When the entire data sets of variants from each
FIG. 4. Frequency and alignment of Rev amino acid (a.a.) sequences obtained from the pony 625 inoculum and sequential serum samples. The
frequency (N) and variant identity (V) are given for each time point, and the total number of clones sequenced is indicated below the N column.
Sequences are compared to R93, which is the dominant variant in the pony 625 inoculum. For individual sequences, a dot indicates an amino acid
identical to R93 at that position, an asterisk indicates a premature stop codon in the rev open reading frame, and a plus sign indicates a frameshift.
DPI, days postinfection.
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pony were analyzed together, pony 625 clade A variants
grouped with pony 524 clade A variants and pony 625 clade B
variants grouped with pony 524 clade B variants (Fig. 5b).
Thus, the two subpopulations of Rev showed greater similarity
between ponies than within ponies.
Subpopulations of Rev quasispecies coexist in vivo. In each
horse, most time points sampled contained variants represen-
tative of both subpopulations of Rev quasispecies. To more
specifically characterize the temporal relationship between the
two subpopulations, we developed a computer program, des-
ignated partition analysis of quasispecies (PAQ), to detect
natural partitions, or groups, of nucleotide variants at each
time point (3). The program uses the Hamming distance as a
measure of distance between rev/tm genotypes and employs a
nonhierarchical clustering method to define grouping of the
variants, represented graphically as circles. Each group con-
tains a central genotype, which is the genotype most represen-
tative of all other variants within the group. Application of
PAQ to the rev/tm data sets indicated that for each pony, most
time points could be partitioned into two or three groups, each
with a radius of three nucleotide differences or less (Fig. 6).
Statistical analysis confirmed that the mean distance among
variants within a group was significantly smaller than the mean
distance among variants between groups (P  0.01). In both
ponies, there was 90 to 100% correlation between the partition
grouping and the phylogenetic grouping of the variants. There-
fore, the PAQ analyses supported the phylogenetic results,
providing further evidence that multiple subpopulations of
EIAV Rev variants coexisted in vivo.
PAQ analysis of the pony 524 rev/tm data set identified three
partition groups, designated groups 1, 2, and 3, which corre-
sponded to clades A, B, and C, respectively, in the Rev phy-
logenetic tree. All groups were defined with a similar radius
value; however, the proportion of sequences found within each
group was highly variable over the course of infection (Fig. 6a).
The greatest proportion of variants in the inoculum and in
samples isolated during the acute stage partitioned into group
2, with R1 as the predominant Rev variant and central geno-
type at each of those time points. The chronic stage of disease
was characterized by an expansion of group 1 and a concom-
itant decrease in the proportion of variants in group 2.
Throughout infection, the proportion of variants in group 1
was minor when group 2 variants were predominant and pre-
dominant when group 2 variants were minor. The fact that
changes in predominance coincided with changes in the clinical
stage of disease suggested that groups 1 and 2 represent two
distinct subpopulations that differ in selective advantage.
Group 1/clade A variants appeared to have had a selective
advantage in the in vivo environment present during the
chronic and late chronic stages of disease, whereas group
2/clade B variants were better suited to the environment
present during the acute and inapparent stages.
Analysis of the pony 625 rev/tm data set with PAQ identified
two groups of viral variants, designated groups 1 and 2 (Fig.
6b). As with pony 524, there was concordance between the
phylogenetic grouping and the partitioning. Clade A/group 1
variants were predominant in the inoculum and at each time
point sampled, while clade B/group 2 variants persisted as a
minor population. The two ponies differed with respect to the
subpopulation that was predominant in the inoculum and dur-
ing the acute stage of disease. Clade B/group 2 was predomi-
nant in the pony 524 inoculum and during the acute stage of
FIG. 5. Phylogenetic analysis of Rev variants. (A) Neighbor-joining tree of the pony 625 Rev amino acid variants based on p distance. The tree
is divided into 2 clades, designated clades A and clade B. The Rev variants highlighted by yellow boxes were biologically assayed for Rev activity.
(B) Neighbor-joining tree of the combined pony 524 and pony 625 Rev amino acid variants based on p distance. Solid lines indicate pony 524
variants, and dashed lines indicate pony 625 variants.
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disease, whereas clade A/group 1 was predominant in the pony
625 inoculum and acute stage of disease. From these data, it
appears that predominance of the Rev subpopulations during
the acute stage of infection was not due to selective pressures
exerted during transmission, but rather to a founder effect
from the inoculum. In contrast to pony 524, dynamic changes
in predominance between the two groups were not observed in
pony 625. This may be due, in part, to the fact that the clinical
disease course in pony 625 did not progress beyond the chronic
stage of disease. Despite these differences, the PAQ analysis of
pony 625 variants clearly demonstrated that minor subpopula-
tions of rev/tm quasispecies can persist in EIAV-infected
horses.
Subpopulations of Rev differ in phenotype. The phylogenetic
and partition analyses identified two subpopulations of Rev
variants that appeared to coexist and differ in selective advan-
tage. To determine whether there were phenotypic differences
between the two Rev subpopulations, we used a chloramphen-
icol acetyltransferase (CAT) reporter system to quantitate the
nuclear export activity of the central genotype from each of the
partitions as well as representative variants from the phyloge-
netic trees. A total of 17 variants from ponies 524 and 625 were
tested for Rev phenotype. These variants represented 67% of
the rev quasispecies sampled in pony 524 and 54% of the
population sampled in pony 625. For each variant, CAT activ-
ity was normalized to the activity level of R1, the founder
variant in pony 524 (Fig. 7a), and results are reported as Rev
activity relative to R1. For 16 of the 17 variants tested, Rev
activity segregated according to the genetic groups identified
by phylogenetic and partition analyses. Furthermore, Rev ac-
tivity of all variants from clade A was significantly higher than
the activity of all variants from clade B (P  0.0001), and the
nuclear export activity of Rev variants within group 1 was
significantly higher than the activity of variants within group 2
(P  0.0001).
To assess if differences observed in transient assays would be
biologically significant in the context of replicating virus, we
constructed chimeric viruses in which rev/tm variants were in-
serted in the backbone of the infectious molecular clone of
EIAV, pSPEIAV19 (34). Chimeric viruses generated from Rev
variants representative of either clade A (R53) or clade B (R1,
R2) were assayed for replication phenotype in equine dermal
(ED) cells. R1 and R2 chimeric proviruses replicated more
slowly and to lower levels than parental SPEIAV19 virus or
R53 chimeric provirus in ED cells (Fig. 6b). Hence, the differ-
ences in Rev phenotype detected in transient transfection as-
FIG. 6. Partition analysis identifies two coexisting subpopulations of rev variants. The groups present at each time point were found with the
program PAQ (3). The relative size of each group represents the proportion of the population contained within the group at that time point. The
central Rev variant for each group is shown, and the arrows show from which group the central variant likely evolved. Groups that overlap indicate
that both groups share at least one variant. For each pony, variants within the same group were generally found within the same clade of the
phylogenetic trees (shown in Fig. 3 and 5) and the color of the group corresponds to the clade from which most variants were found. The different
groups were designated group 1 (red), group 2 (blue), and group 3 (green). The day postinfection and clinical stage of infection are indicated.
(A) Partition analysis of pony 524 rev nucleotide variants at sequential times following infection. (B) Partition analysis of pony 625 rev nucleotide
variants at sequential times following infection.
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says translated to differences in levels of virus replication in
vitro. These differences in phenotype support our interpreta-
tion of PAQ that changes in predominance of groups 1 and 2
over the course of infection were due to differences in selective
advantage.
Variation in Rev is not associated with covariation in the
RRE. Rev is a nucleocytoplasmic shuttling protein that binds to
a specific sequence on the viral pre-mRNA, designated the
Rev-responsive element (RRE). We recently mapped the
EIAV RRE to a 57-nucleotide purine-rich sequence in the 5
portion of env, in a region that also encodes the first exon of
Rev (6). It is possible that the genotypic variation we observed
in Rev exon 2 was accompanied by compensatory covariation
in the RRE. If so, our biological assessment of Rev activity may
not accurately reflect Rev activity in vivo.
To detect covariation in Rev and the RRE, a 230-nucleotide
region encompassing the RRE was amplified by RT-PCR and
cloned, and individual clones were sequenced. RRE variation
in pony 524 was analyzed with five sequential plasma samples,
representing the inoculum and each clinical stage of disease.
Four clones were sequenced from each time point, and there
was 100% nucleotide sequence identity among the 20 clones
(not shown). Furthermore, the RRE sequence found in the 20
clones was identical to the RRE in the Rev reporter assay used
for biological characterization of Rev variations. The finding
that the RRE does not covary with Rev indicates that observed
differences in Rev phenotype are due to the observed genetic
changes in Rev. The high degree of genetic conservation in the
RRE is in marked contrast to that found in Rev exon 2 and
provides additional evidence that genetic and phenotypic vari-
ation in Rev may contribute to EIAV selection in vivo.
DISCUSSION
These studies provide experimental evidence that a viral
quasispecies may comprise multiple subpopulations that evolve
independently and possess distinct selective advantages. Phy-
logenetic analysis of the Rev quasispecies in two EIAV-in-
fected ponies identified two subpopulations of variants that
differed in their genetic divergence and pattern of evolution.
Multiple subpopulations of Rev variants were also detected
with partition analyses, which showed that the subpopulations
coexisted in vivo and fluctuated in predominance over the
course of disease. Transient expression assays demonstrated
that the two subpopulations differed in Rev-dependent nuclear
export activity. Chimeric proviral clones containing rev/tm se-
quences representative of each subpopulation demonstrated
that the differences in nuclear export activity also translated to
differences in the rate and overall level of replication in vitro.
Taken together, these results indicate that the rev/tm quasispe-
cies formed two subpopulations that coexisted over the course
of infection and differed in Rev phenotype. Subpopulations
that differ in phenotype would be predicted to occupy different
regions on the fitness landscape and rapidly respond to
changes in the landscape topology. Such a model may provide
additional insight as to how viruses adapt so quickly to changes
in the host environment.
Several studies have reported the presence of genetically
distinct populations of HIV-1 in different infected organs and
even in different regions within the same organ (1, 35, 39–41).
Anatomical sequestration of virus populations may provide a
biological niche that could lead to the subdivision of the qua-
sispecies into smaller, semi-isolated groups that differ in phe-
notype and/or selective advantage. For example, the differen-
tial expression of HIV-1 coreceptors on CD4 subsets was
associated with the coexistence and independent evolution of
HIV-1 viruses that differed in syncytium-inducing phenotype
(39). Our analyses of the evolution of Rev quasispecies during
progression of EIA disease included over 400 rev/tm se-
quences. Although they were derived from only two experi-
mentally infected ponies and the genetic variation within the
entire data set of rev/tm variants was relatively low, each of the
genotypic and phenotypic assays pointed to the same conclu-
sion: two coexisting subpopulations within the Rev quasispe-
cies that differed not only genetically but also phenotypically.
Furthermore, the changes in population size coincided with
changes in disease state. Together, these data strongly suggest
FIG. 7. Subpopulations of Rev differ in phenotype. (A) Nuclear export activity of pony 524 variants (solid bars) and pony 625 variants (striped
bars) are reported relative to the activity of R1. Results represent the mean activity of at least 9 independent transfections  standard error of
the mean. Variants that differed significantly from the activity of R1 are indicated; *, P  0.05; **, P  0.005; and ***, P  0.00005. (B) In vitro
replication of Rev chimeric virus. Chimeric proviruses representative of clade A/group 1 variants (R53) and clade B/group 2 variants (R1 and R2)
were constructed in the backbone of pSPEIAV19. Virus stocks were produced from stably transfected cell lines, normalized by RT activity, and
inoculated in duplicate onto equine dermal cells. Supernatant was collected every other day and assayed for virion production by RT activity (8).
RT activity was quantified with a phosphorimager, and the results of a representative experiment are shown.
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the presence of subpopulations of Rev that occupied distinct
biological niches, which differed in selective advantage during
progression of disease.
Genotypes representative of the two subpopulations of Rev
quasispecies exhibited significant differences in biological ac-
tivity, as measured by transient transfection assays and chi-
meric provirus replication experiments. The chronic stage of
disease was predominated by variants that had higher Rev
activity, while the inapparent stage of disease was character-
ized by a predominance of variants with lower Rev activity.
These findings agree with the statistical analyses of quasispe-
cies Rev activity in pony 524, which showed that the clinical
stages of EIAV infection were correlated with Rev activity (4).
The fact that similar conclusions were reached via different
computational and genetic approaches supports the hypothesis
that Rev phenotype contributes to variant selection in vivo. At
this time, however, the in vivo selection pressures on these two
subpopulations of Rev variants are unknown.
Recent studies by Bobbitt et al. (7) demonstrated that vari-
ation in HIV-1 Rev activity can alter sensitivity to CTL killing
by downmodulating viral late gene expression. A single amino
acid substitution in HIV-1 Rev resulted in a two- to threefold
reduction in Gag expression and a significant decrease in CTL
killing. Furthermore, primary HIV-1 isolates from asymptom-
atic patients showed reduced Rev activity, reduced levels of
Gag expression, and increased resistance to CTL killing. Sim-
ilar to our results, these findings indicate that limited amino
acid changes in Rev can attenuate activity and may confer a
selective advantage in vivo. While changes in the cytoplasmic
region of TM and/or changes in cytotoxic T-cell epitopes may
also contribute to variant selection, it is reasonable to hypoth-
esize that attenuation of Rev activity may be advantageous for
viral persistence in the presence of a significant host immune
response. Ongoing studies in additional EIAV-infected horses
will increase our understanding of the role of Rev variation in
immune evasion and viral persistence.
The coexistence of multiple subpopulations within a viral
quasispecies implies the persistence of minor subpopulations
of viral variants that have reduced fitness relative to variants in
the predominant population. This impacts our understanding
of how virus populations evolve and how their evolution may
be modeled. Multiple coexisting subpopulations that differ in
selective advantage would occupy different regions on a fitness
landscape and would allow the virus to adapt rapidly to
changes in the host environment by expanding minor popula-
tions that may be near new fitness peaks. This may be espe-
cially relevant in modeling reservoirs of persistent replicating
virus and the emergence of virus variants. For example, failure
of antiviral drug therapy can arise from de novo generation of
resistant variants due to incomplete suppression of replicating
virus or from selection of a minor pool of existing resistant
variants.
In a quasispecies model where there is only one population
of variants, existing resistant variants are rare, and drug resis-
tance would result from the accumulation and fixation of mu-
tations that reduce susceptibility to therapy. In a model with
multiple subpopulations, an existing minor pool of less fit ge-
notypes may include resistant variants or variants that require
fewer point mutations to confer drug resistance. In this model,
the changes in fitness landscape following the onset of antiviral
therapy would induce rapid expansion of the minor subpopu-
lation of resistant variants and persistence of drug-sensitive
variants as the minor population. The latter model may help
explain the rapid rebound of wild-type virus observed in some
HIV-1 patients undergoing structured treatment interruptions
(9, 10, 12, 33). Further examination of the genetic and pheno-
typic complexity of virus populations in vivo will aid our un-
derstanding of quasispecies structure and lentivirus evolution.
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